Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company, has announced a conference call and webcast scheduled for August 14, 2024, at 8:30 a.m. ET. The event will cover two main topics:
1. The company's financial results for the second quarter ended June 30, 2024.
2. An overview of preliminary topline results from Part 2 of the Phase 2 trial of VP-315 for the treatment of basal cell carcinoma.
Interested parties can join via phone or webcast. The webcast will be archived on Verrica's website for 90 days after the event.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), un'azienda specializzata in terapie dermatologiche, ha annunciato una conference call e un webcast programmati per il 14 agosto 2024, alle 8:30 ET. L'evento tratterà due argomenti principali:
1. I risultati finanziari per il secondo trimestre chiuso il 30 giugno 2024.
2. Un riepilogo dei risultati preliminari generali della Parte 2 della sperimentazione di Fase 2 di VP-315 per il trattamento del carcinoma basocellulare.
Le parti interessate possono partecipare tramite telefono o webcast. Il webcast sarà archiviato sul sito web di Verrica per 90 giorni dopo l'evento.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), una empresa de terapias dermatológicas, ha anunciado una conferencia telefónica y un webcast programados para el 14 de agosto de 2024, a las 8:30 a.m. ET. El evento cubrirá dos temas principales:
1. Los resultados financieros del segundo trimestre finalizado el 30 de junio de 2024.
2. Una visión general de los resultados preliminares generales de la Parte 2 del ensayo de Fase 2 de VP-315 para el tratamiento del carcinoma basocelular.
Las partes interesadas pueden unirse por teléfono o webcast. El webcast se archivará en el sitio web de Verrica durante 90 días después del evento.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), 피부치료 회사가 2024년 8월 14일 오전 8시 30분 ET에 예정된 전화 회의 및 웹캐스트를 발표했습니다. 이 이벤트는 두 가지 주요 주제를 다룰 것입니다:
1. 2024년 6월 30일에 종료된 2분기 재무 결과.
2. VP-315의 기초 세포 암 치료를 위한 2단계 임상시험 2부의 초기 전체 결과 개요.
관심 있는 당사자는 전화 또는 웹캐스트를 통해 참여할 수 있습니다. 웹캐스트는 이벤트 후 90일 동안 Verrica의 웹사이트에 보관됩니다.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), une entreprise spécialisée dans les thérapies dermatologiques, a annoncé une conférence téléphonique et un webcast programmés pour le 14 août 2024 à 8h30 ET. L'événement portera sur deux principaux sujets :
1. Les résultats financiers du deuxième trimestre clos le 30 juin 2024.
2. Un aperçu des résultats préliminaires globaux de la Partie 2 de l'essai de Phase 2 de VP-315 pour le traitement du carcinome basocellulaire.
Les parties intéressées peuvent participer par téléphone ou via le webcast. Le webcast sera archivé sur le site de Verrica pendant 90 jours après l'événement.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), ein Unternehmen für dermatologische Therapeutika, hat einen Konferenzanruf und ein Webcast angekündigt, die für den 14. August 2024, um 8:30 Uhr ET geplant sind. Die Veranstaltung wird zwei Hauptthemen behandeln:
1. Die Finanzergebnisse für das zweite Quartal, das am 30. Juni 2024 endete.
2. Ein Überblick über die vorläufigen Gesamtergebnisse aus Teil 2 der Phase-2-Studie von VP-315 zur Behandlung von Basaliomen.
Interessierte Parteien können telefonisch oder über das Webcast teilnehmen. Das Webcast wird 90 Tage nach der Veranstaltung auf der Website von Verrica archiviert.
- Verrica will release preliminary topline results from Part 2 of Phase 2 trial of VP-315 for basal cell carcinoma treatment
- None.
WEST CHESTER, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 14, 2024, to discuss the Company's financial results for the second quarter ended June 30, 2024, and provide an overview of topline results from Part 2 of the Phase 2 trial of VP-315 for the treatment of basal cell carcinoma.
Individuals may participate in the live call via telephone by dialing 1-800-579-2543 (domestic) or 1-785-424-1789 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.
A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. On July 21, 2023, YCANTH® (cantharidin), became the first treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
Terry Kohler
Chief Financial Officer
tkohler@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Chris Calabrese
LifeSci Advisors
ccalabrese@lifesciadvisors.com
FAQ
When will Verrica Pharmaceuticals (VRCA) report its Q2 2024 financial results?
What clinical trial results will Verrica Pharmaceuticals (VRCA) discuss on August 14, 2024?
How can investors access Verrica Pharmaceuticals' (VRCA) Q2 2024 earnings call?
What is VP-315, the drug candidate Verrica Pharmaceuticals (VRCA) is testing?
